Aydin, 20081212 Aydin Y, Berker D, Direktör N, et al. Is insulin lispro safe in pregnant women: Does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract 2008;80(03):444-448. Doi: 10.1016/j.diabres.2008.02.004 https://doi.org/10.1016/j.diabres.2008.0...
|
Observational |
86 |
Regular |
Lispro |
Previous DM + GDM |
Congenital anomalies were more frequent with lispro and similar with regular insulin, but HbA1c was lower. Other outcomes were similar. |
Balaji, 20121313 Balaji V, Balaji MS, Alexander C, et al. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecol Endocrinol 2012;28(07):529-532. Doi: 10.3109/ 09513590.2011.650661
|
RCT |
320 |
Premixed human 30(BIH 30) |
Premixed aspart 30 (BIAsp 30) |
GDM |
BIAsp 30 was not inferior than BIH 30, with comparable fetal results. Based on final dosages, BIAsp 30 may offer a better potential of treatment. |
Banerjee, 20091414 Banerjee M, Bhattacharya A, Hughes SM, Vice PA. Efficacy of insulin lispro in pregnancies complicated with pregestational diabetes mellitus. Pract Diabetes Int 2009;26:366-370. Doi: 10.1002/pdi.1423 https://doi.org/10.1002/pdi.1423...
|
Observational |
153 |
Regular |
Lispro |
Previous DM |
Lispro provides a better glycemic control and does not adversely affect maternal and fetal results. |
Bhattacharyya, 20011515 Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy. QJM 2001;94(05):255-260
|
Observational |
220 |
Regular |
Lispro |
Previous DM + GDM |
No increase in the adverse results was found with Lispro insulin. The satisfaction of the patients favored Lispro. |
Chico, 20101616 Chico A, Saigi I, García-Patterson A, et al. Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin. Diabetes Technol Ther 2010;12(12):937-945. Doi: 10.1089/dia.2010.0111 https://doi.org/10.1089/dia.2010.0111...
|
Observational |
315 |
Regular |
Lispro |
Previous DM |
Lispro was independently associated with less hypoglycemic comas. Its impact on the fetus was favorable or unfavorable, depending on the specific result. |
Chico, 20161717 Chico A, Herranz L, Corcoy R, et al; GEDE (Group of Diabetes and Pregnancy of the Spanish Diabetes Association). Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. Eur J Obstet Gynecol Reprod Biol 2016;206:84-91. Doi: 10.1016/j.ejogrb.2016.07.490 https://doi.org/10.1016/j.ejogrb.2016.07...
|
Observational |
1,210 |
NPH |
Glargina |
Previous DM |
The type of base insulin was independently associated with metabolic outcomes and fetal endpoints. |
Colatrella, 20131818 Colatrella A, Visalli N, Abbruzzese S, Leotta S, Bongiovanni M, Napoli A. Visalli N, Abbruzzese S, Leotta S, BongiovanniM, Napoli A. Comparison of insulin lispro protamine suspension with NPH insulin in pregnant women with type 2 and gestational diabetes mellitus: maternal and perinatal outcomes. Int J Endocrinol 2013; 2013:151975. Doi: 10.1155/2013/151975 https://doi.org/10.1155/2013/151975...
|
Observational |
89 |
NPH |
Insulin lispro protamine |
Previous DM + GDM |
The result with Lispro Protamine insulin was similar to NPH, except for a smaller need for insulin. |
Cypryk, 20041919 Cypryk K, Sobczak M, Pertynska-Marczewska M, et al. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit 2004;10(02):PI29-PI32
|
Observational |
71 |
Regular |
Lispro |
Previous DM |
The course of pregnancy and perinatal results were comparable. Humalog seems to be a safe alternative to human insulin. |
Dalfra, 20152020 Dalfrà MG, Soldato A, Moghetti P, et al. Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study. J Matern Fetal NeonatalMed 2016;29(07):1061-1065. Doi: 10.3109/14767058.2015.1033619 https://doi.org/10.3109/14767058.2015.10...
|
Observational |
933 |
NPH |
Insulin lispro protamine |
Previous DM + GDM |
The association of ILPS with fast action analogs during pregnancy is safe regarding maternal and fetal results. |
Durnwald, 20082121 Durnwald CP, Landon MB. A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonatal Med 2008;21(05):309-313. Doi: 10.1080/14767050802022797 https://doi.org/10.1080/1476705080202279...
|
Observational |
107 |
Regular |
Lispro |
Previous DM |
Lispro showed a better glycemic control and a smaller need for total insulin during pregnancy. Perinatal results were similar. |
Egerman, 20092222 Egerman RS, Ramsey RD, Kao LW, et al. Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol 2009;26(08):591-595. Doi: 10.1055/s-0029-1220782 https://doi.org/10.1055/s-0029-1220782...
|
Observational |
114 |
NPH |
Glargine |
Previous DM + GDM |
Neonatal or maternal adverse effects were not observed with the use of Glargine insulin. |
Fang, 20092323 Fang YM, MacKeen D, Egan JF, Zelop CM. Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med 2009;22(03): 249-253. Doi: 10.1080/14767050802638170 https://doi.org/10.1080/1476705080263817...
|
Observational |
112 |
NPH |
Glargine |
Previous DM + GDM |
Glargine is not associated with the increase of maternal and neonatal morbidity. On previous DM, Glargine was associated with less macrosomia, hypoglycemia, and neonatal hyperbilirubinemia. |
García-Dominguez, 20112424 García-Domínguez M, Herranz L, Hillman N, et al. Use of insulin lispro during pregnancy in women with pregestational diabetes mellitus. Med Clin (Barc) 2011;137(13):581-586. Doi: 10.1016/j. medcli.2010.11.021 https://doi.org/10.1016/j...
|
Observational |
351 |
Regular |
Lispro and Aspart |
Previous DM |
Analogs are safe on previous DM. Glycemic control and maternal and fetal results were similar. Analogs significantly reduced severe hypoglycemia on the mother. |
Heller, 20102525 Heller S, Damm P, Mersebach H, et al. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study. Diabetes Care 2010;33(03): 473-477. Doi: 10.2337/dc09-1605 https://doi.org/10.2337/dc09-1605...
|
RCT |
223 |
Regular |
Aspart |
Previous DM |
The beginning of treatment with insulin analogs at preconception, instead of at the beginning of pregnancy, may result in a smaller risk of severe hypoglycemia in women with DM1. |
Herrera, 20152626 Herrera KM, Rosenn BM, Foroutan J, et al. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes. Am J Obstet Gynecol 2015;213(03):426. e1-426.e7. Doi: 10.1016/j.ajog.2015.06.010 https://doi.org/10.1016/j.ajog.2015.06.0...
|
RCT |
87 |
NPH |
Detemir |
Previous DM + GDM |
Detemir is not inferior to NPH for the treatment of GDM and of DM2 during pregnancy. |
Hod, 20082727 Hod M, Damm P, Kaaja R, et al; Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008;198(02):186. e1-186.e7. Doi: 10.1016/j.ajog.2007.08.005 https://doi.org/10.1016/j.ajog.2007.08.0...
|
RCT |
268 |
Regular |
Aspart |
Previous DM |
Fetal outcome using Aspart was comparable to human insulin with a trend to less fetal losses and premature births. |
Hod, 20142828 Hod M, Mathiesen ER, Jovanovic L, et al. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med 2014;27(01):7-13. Doi: 10.3109/14767058.2013.799650 https://doi.org/10.3109/14767058.2013.79...
|
RCT |
310 |
NPH |
Detemir |
Previous DM |
Detemir is as well tolerated as NPH regarding perinatal results in pregnant women with DM1, with no safety issues. |
Imbergamo, 20082929 Imbergamo MP, Amato MC, Sciortino G, et al. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther 2008;30(08):1476-1484. Doi: 10.1016/j.clinthera.2008.08.013 https://doi.org/10.1016/j.clinthera.2008...
|
Observational |
30 |
NPH |
Glargine |
Previous DM |
There was no significant difference in the glycemic control between glargine and NPH insuline. Use of glargine was associated with a significantly higher frequency of femoral length < 50th centile. |
Jovanovic, 19993030 Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999;22(09):1422-1427
|
RCT |
42 |
Regular |
Lispro |
GDM |
Lispro insulin may be considered as a treatment option for women with GDM. |
Lapolla, 20083131 Lapolla A, DalfràMG, Spezia R, et al. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol 2008;45(01):61-66. Doi: 10.1007/s00592-008-0024-0 https://doi.org/10.1007/s00592-008-0024-...
|
Observational |
370 |
Regular |
Lispro |
Previous DM |
There was a trend for less episodes of hypoglycemia in the Lispro group and also a significant reduction on HbA1c during the first trimester. The congenital malformation rates were similar. |
Loukovaara, 20033232 Loukovaara S, Immonen I, Teramo KA, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2003;26(04):1193-1198. Doi: 10.2337/diacare.26.4.1193 https://doi.org/10.2337/diacare.26.4.119...
|
Observational |
69 |
Regular |
Lispro |
Previous DM |
Lispro insulin improves the glycemic control during pregnancy with no adverse impact on the progression of diabetic retinopathy. |
Mathiesen, 20073333 Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30(04):771-776. Doi: 10.2337/dc06-1887 https://doi.org/10.2337/dc06-1887...
|
RCT |
322 |
Regular |
Aspart |
Previous DM |
Aspart is as safe and effective as human insulin when in base therapy with NPH insulin and may offer some benefits for postprandial glycemic control and for the prevention of severe hypoglycemia. |
Mathiesen, 20123434 Mathiesen ER, Hod M, Ivanisevic M, et al; Detemir in Pregnancy Study Group. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 2012;35(10):2012-2017. Doi: 10.2337/dc11-2264 https://doi.org/10.2337/dc11-2264...
|
RCT |
310 |
NPH |
Detemir |
Previous DM |
Treatment with detemir resulted in lower FPG and noninferior A1C in late pregnancy compared with NPH insulin. Rates of hypoglycemia were comparable. |
Negrato, 20103535 Negrato CA, Montenegro RM Jr, Mattar R, et al. Dysglycemias in pregnancy: from diagnosis to treatment. Brazilian consensus statement. Diabetol Metab Syndr 2010;2:27. Doi: 10.1186/1758-5996-2-27 https://doi.org/10.1186/1758-5996-2-27...
|
Observational |
138 |
NPH |
Glargine |
Previous DM + GDM |
The use of glargine since preconception until birth showed safety because it is associated with a reduction in adverse maternal and neonatal outcomes when compared with NPH. |
Persson, 20023636 Persson B, Swahn ML, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 2002;58(02):115-121
|
RCT |
33 |
Regular |
Lispro |
Previous DM |
It is possible to obtain a proper glycemic control with Lispro, as well as with regular insulin, in pregnant women with DM1. |
Pettit, 20073737 Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med 2007;24(10):1129-1135. Doi: 10.1111/ j.1464-5491.2007.02247.x
|
RCT |
27 |
Regular |
Aspart |
GDM |
Aspart was more effective than regular insulin in the reduction of postprandial glycemia. General safety and effectiveness were similar. |
Price, 20073838 Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 2007;114(04): 453-457. Doi: 10.1111/j.1471-0528.2006.01216.x https://doi.org/10.1111/j.1471-0528.2006...
|
Observational |
64 |
NPH |
Glargine |
Previous DM + GDM |
The use of Glargine during pregnancy may not be associated with an increase of macrosomia and of neonatal morbidity. |
Pöyhönen-Alho, 20073939 Pöyhönen-Alho M, Rönnemaa T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand 2007;86(10):1171-1174. Doi: 10.1080/00016340701515282 https://doi.org/10.1080/0001634070151528...
|
Observational |
91 |
NPH |
Glargine |
Previous DM |
Glargine is comparable to NPH on DM1. No adverse effect was associated with Glargine on the moment of conception and during pregnancy. |
Vellanki, 20164040 Vellanki P, Umpierrez G. Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus. Evid Based Med 2016;21(03):104-105. Doi: 10.1136/ebmed-2015-110309 https://doi.org/10.1136/ebmed-2015-11030...
|
RCT |
87 |
NPH |
Detemir |
Previous DM + GDM |
Detemir is effective and did not increase the risk of fetal or maternal adverse outcomes on GDM and previous DM. |